Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clifutinib food effect in healthy subjects
NCT05454098Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Nov 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of clifutinib in acute myeloid leukemia (AML) (2 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Maximum Plasma Concentration at 4 weeks and Area Under the Concentration-Time Curve From Time Zero to Infinity at 4 weeks. Started Nov 2022; status: completed.
02
Drugs
clifutinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05454098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05454098.